<span item_type="fundamental" item_id="9802796e52323bf88cfd961425eee110" counter_id="ST/US/ICUCW" env="prod"></span><span item_type="announcement" item_id="516116227385131393" env="prod"></span><p>Revenue: As of FY2025 Q1, the actual value is USD 293 K.</p><p>EPS: As of FY2025 Q1, the actual value is USD -0.44.</p><p>EBIT: As of FY2025 Q1, the actual value is USD -3.822 M.</p><p></p><h3>Segment Revenue</h3><ul><li>Net revenue for the three months ended March 31, 2025, was $293,000, compared to $0 for the same period in 2024, as the company commenced commercial sales in July 2024 following FDA approval.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1831868/000095017025071583/icu-20250331.htm"></span></li></ul><h3>Operational Metrics</h3><ul><li>Loss from operations for the three months ended March 31, 2025, was -$3,822,000, compared to -$3,950,000 for the same period in 2024, reflecting a slight improvement.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1831868/000095017025071583/icu-20250331.htm"></span></li><li>Research and development expenses increased by 43% to $2,431,000 for the three months ended March 31, 2025, from $1,697,000 in the same period in 2024, primarily due to increased clinical trial costs and personnel expenses.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1831868/000095017025071583/icu-20250331.htm"></span></li><li>General and administrative expenses decreased by 25% to $1,684,000 for the three months ended March 31, 2025, from $2,253,000 in the same period in 2024, due to declines in accounting, legal, and consulting expenses.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1831868/000095017025071583/icu-20250331.htm"></span></li></ul><h3>Cash Flow</h3><ul><li>Net cash used in operating activities for the three months ended March 31, 2025, was -$2,654,000, compared to -$3,488,000 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1831868/000095017025071583/icu-20250331.htm"></span></li><li>Net cash provided by financing activities for the three months ended March 31, 2025, was $6,131,000, primarily from the issuance of new shares and pre-funded warrants.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1831868/000095017025071583/icu-20250331.htm"></span></li></ul><h3>Unique Metrics</h3><ul><li>The company recognized a gain of $16,000 from the mark-to-market adjustment for liability classified warrants during the three months ended March 31, 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1831868/000095017025071583/icu-20250331.htm"></span></li></ul><h3>Future Outlook and Strategy</h3><ul><li>The company is focused on the commercialization of its pediatric SCD therapy, QUELIMMUNE, and is conducting a pivotal clinical trial for its adult SCD therapy.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1831868/000095017025071583/icu-20250331.htm"></span></li><li>SeaStar Medical Holding Corporation plans to finance its operations through equity or debt sales, borrowings, or collaborations, as it does not expect its current cash reserves to be sufficient for the next 12 months.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1831868/000095017025071583/icu-20250331.htm"></span></li></ul>

SEASTAR MEDICAL HOLDING CORP C/WTS 28/10/2027 (TO PUR COM) | 10-Q: FY2025 Q1 Revenue: USD 293 K